Analysts think DARE stock price could increase by 284%
Aug 29, 2024, 6:26 AM
-5.22%
What does DARE do
Dare Bioscience, a San Diego-based biopharmaceutical company focused on women's health, went public on April 10, 2014, and employs 23 staff. Its FDA-approved product, XACIATO, treats bacterial vaginosis, while its clinical and pre-clinical programs address various women's health issues.
5 analysts think DARE stock price will increase by 284.35%. The current median analyst target is $13.26 compared to a current stock price of $3.45. The lowest analysts target is $12.12 and the highest analyst target is $37.80.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
